Cargando…

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening

Mostrar otras versiones (1)

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emphasized the urgency to develop effective therapeutics. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Wei, Xu, Miao, Chen, Catherine Z., Guo, Hui, Shen, Min, Hu, Xin, Shinn, Paul, Klumpp-Thomas, Carleen, Michael, Samuel G., Zheng, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427131/ https://www.ncbi.nlm.nih.gov/pubmed/32803196 http://dx.doi.org/10.1101/2020.07.17.207019

Ejemplares similares

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
por: Zhu, Wei, et al.
Publicado: (2020)

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry
por: Xu, Miao, et al.
Publicado: (2021)

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry
por: Xu, Miao, et al.
Publicado: (2022)

Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles
por: Chen, Catherine Z., et al.
Publicado: (2020)

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease
por: Liu, Yu-Chih, et al.
Publicado: (2005)

High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
por: Zang, Yi, et al.
Publicado: (2022)

Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL(pro) through high-throughput virtual screening and molecular dynamics simulation
por: Liu, Wen-Shan, et al.
Publicado: (2021)

In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
por: Xiong, Muya, et al.
Publicado: (2022)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor
por: Brown, Alistair S., et al.
Publicado: (2020)

High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2
por: Olubiyi, Olujide O., et al.
Publicado: (2020)

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2020)

Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor
por: Konno, Hiroyuki, et al.
Publicado: (2017)

Evaluation of metal‐conjugated compounds as inhibitors of 3CL protease of SARS‐CoV
por: Hsu, John T.-A., et al.
Publicado: (2004)

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021)

Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen
por: Wang, Liying, et al.
Publicado: (2022)

Inhibition of SARS-CoV 3CL protease by flavonoids
por: Jo, Seri, et al.
Publicado: (2019)

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease
por: Ramajayam, R., et al.
Publicado: (2010)

Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease
por: Shao, Yi-Ming, et al.
Publicado: (2008)

Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection
por: Shamim, Khalida, et al.
Publicado: (2021)

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators
por: Gorshkov, Kirill, et al.
Publicado: (2020)

Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
por: Breidenbach, Julian, et al.
Publicado: (2021)

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
por: Su, Haixia, et al.
Publicado: (2021)

Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021)

An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease
por: Zhai, Tianhua, et al.
Publicado: (2021)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Mechanism of the Maturation Process of SARS-CoV 3CL Protease
por: Hsu, Min-Feng, et al.
Publicado: (2005)

Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening
por: Abdusalam, Ashraf Ahmed Ali, et al.
Publicado: (2020)

Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design
por: Meyer-Almes, Franz-Josef
Publicado: (2020)

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
por: Chen, Catherine Z., et al.
Publicado: (2020)

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
por: Chen, Catherine Z., et al.
Publicado: (2021)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
por: Niesor, Eric J, et al.
Publicado: (2021)

Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety
por: Konno, Sho, et al.
Publicado: (2013)

High Throughput Screening of Protease Inhibitor Libraries Using a Novel Dual Pseudotype-Based Assay for SARS-CoV Entry
por: Zhou, Yanchen, et al.
Publicado: (2009)

Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro)
por: Rothan, Hussin A., et al.
Publicado: (2021)

Protocol for high-throughput screening of SARS-CoV-2 main protease inhibitors using a robust fluorescence polarization assay
por: Zhang, Jing, et al.
Publicado: (2022)

A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors
por: Yan, Haohao, et al.
Publicado: (2022)

Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate
por: Tao, Xuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vljpblimg3oj1uj9285qfhocbc